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ReviewCrohn's disease (CD) is a debilitating condition which still requires improvement in its management. There is
a need for alternatives to anti-tumour necrosis factor drugs which are costly and beneﬁcial in less than 50% of
patients. Intravenous immunoglobulin (IVIG) has been used in the management of aminosalicylate- and
steroid-resistant CD for more than 20 years, although the published literature available is limited. A literature
search identiﬁed 17 relevant publications since 1969, including ﬁve case reports of single patients, two abstracts,
three conference papers, one review paper and six book or journal articles. No randomised controlled trials of
IVIG in CD have been published. A review of the evidence identiﬁed indicates that IVIG can induce a rapid and
signiﬁcant improvement in aminosalicylate- and steroid-resistant CD, oftenwithin days of the initial administra-
tion. Data from longer-term studies show that maintenance of remission over the medium term is also possible.
These encouraging ﬁndings provide a rationale for the initiation of larger randomised controlled trials of IVIG in
CD with the aim of providing further treatment options for this difﬁcult-to-manage condition.
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791. Introduction
In patients with steroid-refractory Crohn's disease (CD), the thera-
peutic goal is to achieve both rapid remission andmaintenance of clinical
response. Both azathioprine and 6-mercaptopurine are successful in in-972 25335564.
tzky).
-NC-ND license.ducing and maintaining remission [1]. However the peak response is
achieved at greater than 17 weeks of therapy and is thus not useful for
rapid induction of remission [1]. Although anti-tumour necrosis factor
(anti-TNF) drugs have proven to be effective in a substantial percentage
of patients with CD, only approximately one-ﬁfth of all CD patients ini-
tially treated with anti-TNF drugs are still in remission after 1 year [2].
The signiﬁcant level of treatment-refractory patients, coupled with the
frequent adverse effects and sometimes signiﬁcant toxicities of existing
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rapid remission in refractory CD.
In this article we review the use of intravenous immunoglobulin
(IVIG) to induce and maintain remission in aminosalicylate- and
steroid-resistant CD. While experience with the use of IVIG for
treating CD has spanned two decades, the total number of patients
thus treated remains relatively small. The primary reason for this is the
high cost of treatment in comparison with aminosalicylates, steroids
and immunosuppressants. However, with the current use of biological
therapies as standard in the treatment of CD, the cost of IVIG therapy
should no longer pose a barrier to its use, while its safety and efﬁcacy
record make it an ideal candidate for large efﬁcacy trials.2. Methodology
This review was designed to cover literature reporting the effects
of IVIG treatment on CD. Searches were performed on the MEDLINE
database (1969–20 Jan 2011) for the search terms immunoglobulin
and Crohn's disease. Additional relevant publications were identiﬁed
by searching the reference lists of articles identiﬁed. In total, these
searches yielded 21 papers, of which one was discarded due to its
method of drug administration [3], one due to the lack of information
about the treatment given [4] and a further two were inaccessible in
either electronic or paper form [5,6]. Studies were translated from
Spanish and German as required. Studies captured include both those
investigating standard IVIG and those investigating IgM-enriched IVIG
(referred to herein as IVIG and IgM-enriched IVIG, respectively).3. Results
3.1. Source data
The small number of publications on this topic spans some
20 years, from 1986 to 2007. They are highly variable in style and
aim, ranging from short case reports to larger studies accompanied
bymechanistic discussion. No common format in terms of data provided
was found. More than half of the papers include the patients' Crohn's
disease activity index (CDAI) prior to immunoglobulin administration,
but there is a plethora of techniques used to indicate the success of the
treatment. Such variety makes standardisation of the results impossible,
so this review addresses each report individually on a case-by-case
basis.
Of the 17 papers considered in this study, ﬁve are case reports of
single patients [7–11]; two are abstracts of papers dealing with larger
groups of patients [12,13]; three are conference papers [14–16]; one
is a review paper [17]; while the remainder are articles either in
books or scientiﬁc journals. No randomised controlled trials of IVIG
in CD have been published in any form. Two of the reports are
based on the use of IgM-enriched IVIG [13,16], while the remaining
studies used IVIG.
There is some duplication of results between studies with the
same authors. In one case this seems to be to allow the implications
of the results to be considered from different perspectives [18–20].
These papers, based upon the same patient data but exploring different
implications of the results, will be amalgamated for the purposes of this
review and referred to as Levine et al. In two further cases, those of
Raedler et al. [13,16] and Schmidt [15,21], earlier publications seem to
have led to a further study involving greater numbers of patients. Dupli-
cation of patient data between the earlier and later publications cannot
be determined with any certainty, and these papers will be considered
separate studies for the purposes of this review.
In summary, the literature offers some 17 relevant publications
detailing 14 separate studies of the use of immunoglobulins in
treating salicylate- and steroid-resistant CD.3.2. Paper details
The relevant papers, in order of publication, are as follows.
Raedler et al. [16] presented the results of a non-randomised,
20-patient trial, with pre-treatment CDAI of 200–300, of whom half
were treatedwith steroids and aminosalicylates andhalfwere addition-
ally given IVIG treatment, using IgM-enriched IVIG (Pentaglobin, Biotest
AG, Germany) at a dosage of 0.25 mL/kg/h, via continuous perfusion
over 4 d. CDAI in the IVIG group decreased to a mean of 180 by Day
14, while in the non-IVIG group the CDAI decreased to 220 over the
same period. C-reactive protein (CRP) count decreased from 3.5 mg/dL
to 1.5 mg/dL over 14 d versus 3.7 mg/dL to 1.9 mg/dL for the control
group. No side effects were reported. The clinical beneﬁts associated
with the decreases in the various markers used were not outlined.
Rohr et al. [17] reported the case of a patient with a 4-week history
of symptoms congruent with CD (diarrhoea, abdominal pain and a 5-kg
weight loss) with a CDAI of 312whowas given anunspeciﬁed dosage of
IVIG (Venimmun, Behring AG, Germany) for 7 d. The authors reported
pain relief occurring on Day 2, a 5-week post-treatment CDAI of 70,
no further abdominal pain and normal stools (veriﬁed at 2 and
5 weeks post-treatment). A colonoscopy at 5 weeks found no signs of
active inﬂammation. There was no relapse within 5 weeks of treatment
and no side effects were reported. Two other patients with a CDAI of
>300 are also noted to be ‘much improved after a few days’ after iden-
tical treatment, but little further detail is given.
Wolf et al. [10] presented a case with over 4 years of symptoms
(bloody diarrhoea, fever and weight loss) and unsuccessful treatment
as well as steroid resistance (previous unsuccessful treatments were
prednisolone at 2 mg/kg/d, cortisone enemas for 6 d, metronidazole
at 20 mg/kg/d and sulfasalazine at 80 mg/kg/d for 2 weeks). A 7-day
course of IVIG (Sandoglobulin, Sandoz AG, Switzerland) at a dosage of
0.4 g/kg/d resulted in an improvement after 2 d of treatment, with the
patient becoming clinically free of symptoms after 5 d. Treatment was
continued twice-weekly for 4 weeks. Two relapses after the initial treat-
mentwere re-treated successfullywith IVIG (with time to recovery being
3 d and 6 d for each relapse, respectively). After an additional relapse,
further remission could be obtained only with steroids.
Raedler et al. [13] presented ten patients with a mean CDAI of 150,
who received 4 d of treatment with IgM-enriched IVIG (Pentaglobin,
Biotest AG, Germany) at a dosage of 2.5 mL/kg/d in addition to steroid
and sulfasalazinemedication. Evaluation of patients on Day 14 revealed
a ‘marked improvement’ in CDAI and other parameters compared with
the control group, and no side effects were reported.
Sorensen and Kallick [11] presented a steroid-resistant 12-year old
patient with a colonoscopy-veriﬁed inﬂamed ileum without abscess
formation, veriﬁed by colonoscopy. IVIG therapy (brand not disclosed)
at a dosage of 1 g/kg/d for 3 d resulted in clinical improvement within
3 d. Monthly IVIG infusions (1 g/kg) enabled the discontinuation of
the steroid dosage. No side effects were reported.
Possoz et al. [12] presented the results of a long-term study of six
steroid-dependent patients, mean age of 26 years, with mean CD-
duration of 56 months. Over the year prior to inclusion, all patients had
at least three relapses of their disease. At the time inclusion, ﬁve patients
had received prednisolone (20 mg/d) andone had receivedprednisolone
(10 mg/d) and mercaptopurine (75 mg/d). At this time, CDAI was lower
than 100. An initial 5-day treatment of IVIG (supplied by CNTS, France) at
a dosage of 0.4 mg/kg/d was followed by treatment every 3 weeks for
33±3 weeks, resulting in remission of all patients with no relapses
and an improved CDAI. Steroid treatment was continued throughout.
Side effects were noted in four patients who reported transitory
headaches, shivers and fever after the ﬁfth round of treatment, ulti-
mately resulting in cessation of treatment.
Schmidt [21] reported three steroid-resistant patients, each
with more than 2 years of symptoms. Cases 1 and 2 involved pa-
tients with 6–13 years of prior symptoms, including ﬁstulae, ab-
dominal pain and weight loss. Prior treatment (azathioprine at
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had been unsuccessful. Case 3 presented with diarrhoea, fever and joint
pains, which had not responded to prednisolone (40 mg/d decreased
to 10 mg/d). Pre-treatment CDAI for Cases 2 and 3was 238 and 120, re-
spectively. All patients were treated with a 10-day course of IVIG
(Venimmun, Behring AG, Germany) at a dosage of 2×5 g/d irrespective
of bodyweight. All patients showed decreased pain and diarrhoea along
with improved serological indications. Post-treatment CDAI for Cases 2
and 3 was 69 and 50, respectively. No side effects were observed.
Knoﬂach et al. [22] reported on six CD patients with a mean CDAI
of 290 (±51) and mean serum alpha protein levels of 259 (±129)
mg/dL. Corticosteroid therapy was discontinued at least 8 weeks
prior to IVIG treatment. A 5-day course of IVIG treatment (Endobulin,
Immuno AG, Austria) at a dosage of 400 mg/kg/d led to resolution of
fever and reduction in abdominal pain for all patients within 2–3 d.
Half of the study group showed reduced CDAI at 16 weeks (mean
CDAI, 170±51), with two patients still in steroid-free remission at
18 and 21 months. The other patients did not maintain response to
the IVIG treatment, with both CDAI and serum alpha protein levels
rising after 2 weeks of IVIG treatment. There were no clear differences
between the patients who did and did not maintain response to the
treatment. No side effects were observed.
Rohr et al. [17] followed up their earlier paper with a review includ-
ing a summary of an earlier study performed by their own groupwhich
was unobtainable for the purposes of this review. According to their
summary, 24 patients with a CDAI of between 200 and 350, with prior
diagnosis of CD by colonoscopy, histology or X-ray, were given a
7-day course of IVIG (Venimmun, Behring AG, Germany) at a dosage of
10 g/d irrespective of bodyweight. Fifteen of these patients had a reduc-
tion of 100 points in CDAI at Day 14, and were considered treatment
successes. Improvements persisted in 12 of these patients after 90 d.
Any extra-intestinal symptoms (joint pains or erythema nodosum in
three patients) were ‘largely alleviated’, but no improvement was ob-
served in the ﬁstulae of three patients. No side effects were reported.
The paper indicates that a randomised controlled trial has been initiated
in this area, but no further details or publications are available on
MEDLINE.
Teuber et al. [14] discuss seven patients with a CDAI of 250–450
(mean CDAI 340±70), three of whom were experiencing ﬁrst-time
manifestations. The remaining patients had been treated with cortico-
steroids and/or sulfasalazine. A 7-day IVIG course (Venimmun, Behring
AG, Germany) at a dosage of 10 g/d irrespective of bodyweight resulted
in a sharp CDAI decrease in six patients over a 4–8 week period (to a
mean CDAI of 143±100). The remaining patient saw an increase in
CDAI from 380 to 650. Three patients with extra-intestinal symptoms
(arthopathy and/or erythema nodosum) experienced remission of
those symptoms, without any improvement in existing ﬁstulae. The
three newly-diagnosed patients were still in remission at 90 d post-
treatment. No side effects were reported.
The group of papers by Ochs, Levine et al. [18–20] presents three pa-
tients with Crohn's colitis. One patient had a 1-year history of symp-
toms including diarrhoea and abdominal cramps, and was being
treated with prednisone (25 mg/d) and corticosteroid enemas. The
two remaining patients had 10-year histories of symptoms, one with
abdominal pain and diarrhoea and the otherwithﬁstulae and abscesses.
These patients were being treated with methylprednisolone (40 mg/d
and 200 mg/d, respectively). All three patients responded to a 5-day
course of IVIG (Sandoglobulin, Sandoz Pharm, US) at a dosage of
400 mg/kg/d. Therapy was continued in one patient for 12 weeks
(400 mg/kg every 2 weeks). Two patients that were given 200 mg/kg
at 2 and 4 weeks, respectively, did not complete the study and showed
no change in their Crohn's colitis activity score. The remaining pa-
tient had a reduction in his Crohn's colitis activity score from 8 to 3 to-
gether with a hiatus in steroid treatment for 3 months until relapse.
Colonoscopy results showed a reduction in inﬂammation. No side ef-
fects due to IVIG treatment were reported.Schmidt's second paper [15] details the results of a study of 19 pa-
tients with a mean disease duration of 10.3 years and a mean CDAI of
200±18. Four of these patients presented ﬁstulae and nine had
extra-intestinal symptoms. Eighteen patients were receiving amino-
salicylates (mean dosage of 2.2 g/d) and 16 were on steroid therapy
(mean dosage of 16.4 mg/d). In addition, two patients were receiving
methotrexate and two patients were receiving azathioprine. After a
10-day IVIG course (Venimmun, Behring AG, Germany) at a dosage of
2×5 g/d irrespective of bodyweight, mean CDAI dropped signiﬁcantly
to 100±9 (pb0.0001) with just three patients seeing improvements
of less than 25%. There was a signiﬁcant reduction in abdominal pain
and bowel movement frequency (mean frequency fell from 4.5/d to
1.8/d; pb0.001). At 6 months of follow-up, the mean CDAI was still sta-
tistically lower than that prior to therapy (p-value not stated). No side
effects were reported.
Korber et al. [7] reported on a single patient with a 3-year history of
CD (symptoms included diarrhoea, cramps and weight loss). Previous
medication (prednisone at 50 mg/d, mesalamine at 1.5–3.0 g/d, metro-
nidazole at 750–1500 mg/d) did not improve the clinical condition. IVIG
(brand not disclosed) at a dosage of 0.4 g/kg was administered every
3 weeks for 9 months, resulting in a marked improvement in the
patient's condition including reduced diarrhoea frequency, cessation
of fever and weight gain. Cessation of therapy led to relapse within a
fewweeks. Restarting therapy resulted in similar levels of improvement
to those initially seen. No side effects were observed.
González-Lara et al. [9] reported a single patient with a 5-year history
of CD (symptoms including fever, abdominal pain, abscesses andﬁstulae).
The patient underwent seven separate operations during this period,
including a bowel resection and removal of an enterovesical ﬁstula.
Previous therapy (mesalamine at 3 g/d, metronidazole at 1.5 g/d and
azathioprine at 50–100 mg/d) had failed. The patient was given a
2-day IVIG course (Flebogamma, Grifols, Spain) at a dosage of 1 g/kg/d,
in addition to paracetamol at 500 mg orally and dexchlorpheniramine
at 5 mg subcutaneously in order to prevent side effects from IVIG.
Draining ﬁstulae resolved from the onset of treatment. A once-monthly
dose of 400 mg/kg for 32 months maintained the improvement in the
patient's health without side effects. Concurrent medications were dis-
continued without complications. No side effects were reported.
Chrissaﬁdou et al. [23] reported 19 steroid-resistant patients with
a mean CDAI of 285±150. Two patients had been unsuccessfully
treated with azathioprine. Ten patients had extra-intestinal manifes-
tations, with ﬁstulae in ﬁve. A course of IVIG was administered as
follows: 12 patients received 10 g/d of Venimmun (Behring AG,
Germany) for 7 d (total dose 70 g); three patients received 10 g/d of
Octagam (Octapharma AG, Switzerland) for 7 d (total dose 70 g);
one patient received 10 g/d of Gamimmune (Bayer AG, Germany) for
7 d (total dose 70 g); two patients received a total dose of 72 g of
Sandoglobin (Sandoz AG, Switzerland) at alternating doses of 6 g/d
and 12 g/d over 10 d, and one patient received a total dose of 90 g
of Sandoglobin (Sandoz AG, Switzerland) over 10 d. IVIG was
administered in addition to pre-existing medications (5-ASA and
corticosteroids at mean dosage of 18.2±4 mg/d). The overall mean
CDAI at the end of therapy had dropped to 212±158. Fourteen pa-
tients were in remission at 4 weeks, with a mean CDAI below 150.
Fourteen patients experienced a CDAI decrease of greater than 100
points. The mean duration of remission for the eight patients
followed up was 20 months. The only side effect reported was a tran-
sient rise in temperature after infusion in one patient.4. Discussion
IVIG is a therapeutic preparation of pooled normal polyspeciﬁc IgG
obtained from plasma pools of healthy blood donors. IVIG is used as a
therapeutic agent in a large number of autoimmune, allergic and in-
ﬂammatory diseases [24].
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aminosalicylate- and steroid-resistant CD patients with IVIG. Although
they differ greatly in methods of measuring improvement in patients,
and in areas of treatment design (frequency, length of treatment, IVIG
brand and use of concurrent medications) the overall picture is one of
a successful amelioration of symptoms and very rapid induction of
remission.
The variation in treatment designs and outcomes is explored in
greater detail in the sections below.
4.1. IVIG type
Unlike recombinant proteins, variations in IVIG products are com-
mon, with differences between commercially available IVIG products
with respect to various parameters including stabilizing agents and
formulation [24].
A number of different IVIG brands were used in these studies.
Pentaglobin, an IgM-enriched IVIG brand, was used in 30 patients in
the two studies of Raedler et al. [13,16]. The remaining studies
used standard IVIG, of which Venimmun (Behring AG, Germany),
which was used by 66 patients in six studies, was by far the most
common brand. Sandoglobulin (Sandoz AG, Austria) was used in
seven patients in three separate studies [10,20,23]. The number of
patients receiving each brand across all studies is shown in Fig. 1.
Owing to the variability of the study designs and, in the case of the less
frequently used brands, the small sample size, no conclusions can be
drawn about the relative effectiveness of enriched-IVIG brands over
standard IVIG, or of one brand over another.
4.2. Dosages
In the majority of studies, an initial course of immunoglobulin was
administered intravenously in a single, daily treatment over a number
of days, typically less than a week. As exceptions, Korber et al. [7] ad-
ministered treatment on a 3-week basis over 9 months, while Raedler
et al. [16] infused “continuously” over 4 d. Themajority of studies report
dosages in mg/kg/d, while Raedler et al. [13] give dosages in mL/kg/d
without stating concentrations and Rohr et al. [8] give no dosages.
Four studies [14,15,21,23] describe a dosage of 10 g/d irrespective of pa-
tient weight. The distribution of dosages, where known, and length of
treatment are shown in Table 1.
4.3. Concurrent medications
Most studies discussed in this review did not permit the use of
other medications concurrently with the IVIG treatment. A number
of studies did allow corticosteroid or immunomodulatory treatment,
as discussed below.Fig. 1. IVIG brands used in the studies covered in this review, sorted by the number of patie
IVIG.Raedler et al. described no precise treatment regimes in either of
their papers, beyond noting that patients were also taking a basic
therapy of steroids and aminosalicylates [13,16]. Wolf et al. [10] treated
their patient with prednisolone (1 mg/kg/d) during the initial IVIG treat-
ment. A later relapse by their patient was treated with prednisolone
(10 mg/kg on alternate days) and salazosulfapyridine (2 g/d) in addition
to the IVIG treatment.
Possoz et al. [12] treated ﬁve of their patients with prednisolone
(20 mg/d) and one with prednisolone (10 mg/d) and mercaptopurine
(75 mg/d).
In the study of Schmidt [15], 18 patients were concurrently treated
with 5-aminosalicylic acid (2.2 g/d mean dosage), and 16 received
steroid therapy (16.4 mg/d mean dosage). González-Lara et al. [9] ad-
ministered paracetamol (500 mg/d orally) and dexchlorpheniramine
(5 mg/d subcutaneously) as prophylaxis of potential IVIG side effects.
The larger study of Chrissaﬁdou et al. [23] recorded patients receiving
a variety of corticosteroids with a mean dosage of 18.2 mg/d.
Data from the studies which permitted concurrent medications as
described above do not in themselves suggest any correlation be-
tween concurrent medications and the success or otherwise of the
IVIG treatment. It should be noted that the reason for initiating the
IVIG treatment in all cases was a failure or insufﬁcient response to
these concurrent treatments.
4.4. Outcomes
4.4.1. CDAI
CDAI data for all studieswhere this information is available are shown
in Fig. 2. Clear and shaded columns represent mean CDAI prior to and
post treatment, respectively. The error bars represent plus one standard
deviation from the mean. The number of patients represented by each
column or column-pair is shown in bold at the base of each column.
The reference for each study is below the horizontal axis in each case.
This ﬁgure shows that themean baseline CDAI in themajority of stud-
ies was over 200. Further, for those studies inwhich post-treatment CDAI
is given, a drop of around 100 points or more is seen relative to the base-
line CDAI score.
Despite the unavoidably subjective nature of the CDAI system, it is
clear from these studies that it plays a useful role in the general clas-
siﬁcation of the severity of the disease, and that it can track an im-
provement in patient symptoms. There are several points to make
on the distribution of CDAI shown in this ﬁgure. First, the baseline
CDAI of patients admitted for immunoglobulin treatment varies
greatly, from a low of around 120 to above 400. Second, where
given, the CDAI of patients after treatment shows a clear decrease
from the baseline in most cases, even allowing for one standard devia-
tion in the post-treatment value. Crucially, this is observed particularly
in those studies comprising the largest numbers of patients. Although
the increase in standard deviation from before treatment to afternts treated across studies. Pentaglobin is an IgM-enriched IVIG; all others are standard
Table 1
Distribution of dosage and length of initial treatment (where given) for the studies
under review.
No.
days
Dosage data
mg/kg/d mg/d
0.4 150 400 1000 10,000
1 2
2 1
3 1
5 1 2
7 1 1 2
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anomalous rise in CDAI for one patient. Excluding this patient gives a
post-treatment CDAI of 145±100.
4.4.2. Treatment length and follow-up
Initial treatment length for the studies under review varied between
2 and 10 d (see Table 1). Follow-up periods varied considerably. The
longest overall studies were González-Lara et al. [9], with a mean dura-
tion of 32 months and Chrissaﬁdou et al. [23], with a mean duration of
20 months. Possoz et al. [12] monitored over 33 weeks, while Schmidt
[15] followed up after 6 months. The studies of Rohr et al. [17] and
Teuber et al. [14] followed up over 90 d. Levine [20] monitored over
12 weeks. Other studies, where follow-ups are mentioned, used a time
frame of 2–4 weeks.
4.4.3. Side effects
Only one study reported side effects of the IVIG treatment. Four of
the six patients in the study by Possoz et al. [12] had transitory head-
aches, shivers and attacks of fever after the ﬁfth round of treatment,
resulting in cessation of treatment. In the study by Chrissaﬁdou et
al. [23], one patient presented a short-term rise in temperature after
infusion.
Two of the three CD patients in the study by Ochs, Levine et al.
[18–20] withdrew before the completion of the treatment, but this
does not appear to have been due to the treatment itself.
4.4.4. Mechanism of action
Few of the studies discussed here attempted to speculate on its
mechanism of action. Of those that proposed a potential mechanism,
Rohr et al. [17] postulated that IVIG inﬂuences the formation ofR
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Fig. 2.Mean CDAI of patients before and after treatment with immunoglobulins, where
given. Error bars represent plus one standard deviation. Number of patients included in
the study is shown in bold at the base of the column. Relevant study reference is shown
below the horizontal axis.immune-complexes, modulating antibody response in anti-idiotypic
antibodies. They assume that this is due to other, unspeciﬁed anti-
bodies in the IVIG preparation. Schmidt [15] advanced the idea that
either immunocomplex formation is suppressed by IVIG administra-
tion, or that existing IVIG deﬁcits are rectiﬁed.
In fact, the mechanism of action of IVIG therapy has been the subject
of considerable research interest among the wider scientiﬁc community.
Although the precise mechanism by which IVIG exerts its immunomod-
ulatory effects is still not fully deﬁned [25], multiple and synergistic
modes of action are known to be involved [26–28]. Speciﬁcally, the
mechanism of action of IVIG is thought to involve the Fc receptor block-
ade, inhibition of complement-mediated damage, modulation of cyto-
kines, neutralization of pathogenic autoantibodies via anti-idiotypic
antibodies or by their downregulation, and neutralization of toxins
that trigger autoantibody production [26]. The primary mechanism of
action is considered to be the blockade of macrophage Fc receptors
[26]. The ability of IVIG to neutralize pathogenic autoantibodies is of
particular interest in relation to the beneﬁts of this treatment in many
autoimmune diseases, including CD [26,29].
4.4.5. Cost–beneﬁt analysis
Aside from medical justiﬁcations for the use of IVIG therapy, there
are also economic reasons for adopting this treatment. Anti-TNF
therapies, in particular, are highly expensive. In the US, the wholesale
acquisition (WAC) price of inﬂiximab is $657.87 per 20 mL vial
(100 mg) [30], leading to a projected cost of $2401 for a single infusion
or $18,007 for a standard 12-month course of administration.1 In view
of this, there remains a need to ﬁnd a more cost-effective therapy
with the ability to induce very rapid response, particularly in patients
who are steroid-resistant, or where steroids would be contraindicated.
While IVIG is also a costly therapy, being reimbursed according to the
Medicare Outpatient Prospective Payment System (OPPS) at a cost of
$73.30/g based on an average of ﬁve brands [31], the total cost of treat-
ment is lower than that of anti-TNF therapies. For example, a 10 g/d
regiment for 7 or 10 d irrespective of bodyweight (as administered
in four of the reports presented in this review [14,15,21,23]) would
cost approximately $5131–$7300, excluding administration costs. Fur-
thermore, the ability of IVIG to induce a rapid remission permits quick
evaluation of the efﬁcacy (or otherwise) of the treatment.
5. Conclusions
The small number of studies available consistently shows that IVIG
treatment in the setting of aminosalicylate- and steroid-resistant CD
can bring about a rapid and clinically signiﬁcant improvement in pa-
tient condition, typically within days of the initial administration.
Data from longer-term studies show that maintenance of remission
over the medium term is also possible. These ﬁndings are encouraging,
but require timely veriﬁcation in the form of large randomised con-
trolled trials in order to better demonstrate the safety and efﬁcacy of
IVIG in the treatment of CD.Take-home messages
• IVIG has been safely used in Crohn's disease for more than 20 years.
• IVIG can induce rapid improvement in CDoftenwithin days, sometimes
leading to lasting remission.
• RCTs are urgently needed in order to evaluate IVIG as an alternative
for patients resistant to anti-TNF therapies.1 Based on a dosage of 5 mg/kg and an average patient weight of 73 kg.
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